Editorial Note: This article is an internal production sample used exclusively for contributor outreach. All content, author bios, and associated data are strictly illustrative and fictional.
This is an opinion article. The author's views are identified as such and are distinguished from the published evidence below.
On August 19, 2026, Merck and Moderna announced that their Phase 3 INTerpath-001 trial had met its main goal. Their investigational therapy, intismeran autogene, combined with the immunotherapy drug Keytruda (pembrolizumab), improved recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in patients whose melanoma had been surgically removed.
